ADP Receptors and Clinical Bleeding Disorders

Arteriosclerosis, Thrombosis, and Vascular Biology - Tập 19 Số 10 - Trang 2281-2285 - 1999
Marco Cattaneo1, Christian Gachet2
1Marco Cattaneo From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center (M.C.), IRCCS Ospedale Maggiore, University of Milano, Milano, Italy, and INSERM U.311 (C.G.), Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France.
2Christian Gachet From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center (M.C.), IRCCS Ospedale Maggiore, University of Milano, Milano, Italy, and INSERM U.311 (C.G.), Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France.

Tóm tắt

Abstract—ADP plays a key role in hemostasis and thrombosis. Despite its early identification in 1961 as the first known aggregating agent, the molecular basis of ADP-induced platelet activation is only beginning to be understood. The present review proposes a model of 3 purinergic receptors contributing separately to the complex process of ADP-induced platelet aggregation: the P2X1ionotropic receptor, responsible for rapid influx of ionized calcium into the cytosol; the P2Y1metabotropic receptor, responsible for mobilization of ionized calcium from internal stores, which initiates aggregation; and an as-yet-unidentified P2Y receptor coupled to Gαi2, which is essential for the full aggregation response to ADP. It is probable that this as-yet-unidentified receptor is the molecular target of the ADP-selective antiaggregating drugs ticlopidine and clopidogrel. In addition, it is probably defective in patients with a bleeding diathesis that is characterized by selective impairment of platelet responses to ADP.

Từ khóa


Tài liệu tham khảo

1997, Thromb Haemost, 76, 835

10.1055/s-0038-1657538

10.1016/S0223-5234(97)83970-0

10.1016/S0889-8588(18)30506-9

10.3109/09537109309013225

10.1016/S0165-6147(00)89018-5

1998, Platelets, 8, 161

1993, Thromb Haemost, 70, 389, 10.1055/s-0038-1649591

1975, Am J Physiol, 228, 1757, 10.1152/ajplegacy.1975.228.6.1757

10.1038/38284

10.1074/jbc.273.4.2024

10.1016/S0014-5793(98)00025-8

1998, . Blood., 92, 152, 10.1182/blood.V92.1.152.413k27_152_159

10.1016/S0014-2999(98)00305-7

10.1111/j.1365-2141.1995.tb05319.x

10.1182/blood.V80.11.2787.2787

10.1016/0014-5793(93)81397-I

10.1016/S0014-5793(97)00022-7

10.1124/mol.53.4.727

10.1074/jbc.273.4.2030

10.1055/s-0037-1614427

1991, Thromb Haemost., 81, 775

10.1046/j.1365-2141.1998.01056.x

10.1055/s-0038-1665441

10.1073/pnas.95.14.8070

10.1172/JCI117835

Cattaneo M Zighetti ML Lombardi R Lecchi A Gachet C Cazenave J-P Mannucci PM. Platelets from a patient heterozygous for the deficiency of 2 MeS-ADP binding sites have a secretion defect. Eur J Clin Invest . 1997;27(suppl 1):A23. Abstract.

10.1055/s-0037-1615230

10.1161/atvb.16.12.1532

10.1046/j.1365-2141.1997.d01-2132.x

10.1055/s-0038-1656090

1998, Blood, 91, 549, 10.1182/blood.V91.2.549

10.1182/blood.V75.5.1081.1081

10.1111/j.1365-2141.1994.tb05123.x

Cattaneo M Randi AM Canciani MT Lecchi A Mannucci PM. Role of ADP in platelet aggregation and fibrinogen binding induced by prostaglandin endoperoxides: studies in a patient with selective defect of ADP-induced platelet aggregation. In: Jamieson GA ed. Platelet Membrane Receptors: Molecular Biology Immunology Biochemistry and Pathology. New York NY: Alan R. Liss; 1988:279–283.

Thông tin
Thông tin xuất bản

Arteriosclerosis, Thrombosis, and Vascular Biology

Tập 19 Số 10

2281-2285

Thông tin tác giả